# Buprenorphine Criteria

[Buprenorphine Criteria](https://mygainwell-my.sharepoint.com/:u:/r/personal/christopher_nguyen_gainwelltechnologies_com/Documents/Evergreen/Bup/FW%20Buprenorphine%20Criteria.msg?csf=1&web=1&e=av1FPF)


Recommended ODM PA Criteria

Buprenorphine mono products will be approved for:

· Pregnancy
· Breastfeeding
· Contraindication to combo products (documented history of serious adverse reactions that can include moderate/severe hepatic impairment, allergies, anaphylaxis, bronchospasm, angioneurotic edema, anaphylactic shock, hives)
	§ Allergy to buprenorphine/naloxone combination product- defined as type I- IgE-mediated hypersensitivity reactions 
	§ Including things such as rash, hives, swelling of the face, wheezing, low blood pressure, and loss of consciousness
	§ Serious adverse reactions do not include symptoms such as:
		○ Headache
		○ Nausea / vomiting 
		○ Dizziness
		○ Diarrhea 
	§ Hepatitis is not a detailed enough diagnosis to determine if naloxone is a contraindication
	§ Intolerances are not approvable as reasons to use mono product

· Conversion from mono (ex. was pregnant and is done breast feeding) to combo product
· Patients who are being treated for use of long-acting opioids (including conversion from methadone)

Mono products will be approved for the following time frames: 
· Initiation:
o Pregnancy: 180 days (max per UPDL)
o Breastfeeding: 180 days (max per UPDL)
o Documented contraindication to combo: 180 days (max per UPDL)
o Conversion from mono to combo: 30 days, max 90 days
o Initiation for long-acting opioids: 30 days, max 90 days
· Maintenance: 180 days, reauth criteria as noted in UPDL/MAT PA form


Other notes:
Side effect profiles for both mono and combo products are similar, including nausea and headaches. 

Prescribing for buprenorphine products must follow the requirements of Ohio Administrative 
Code rule 4731-33-03 Office based treatment for opioid addiction.

Members should not be allowed to take both injectable buprenorphine and oral buprenorphine concomitantly

Each PA request (whether initiation or maintenance) must meet the buprenorphine approval criteria (pregnancy, breastfeeding, etc) and this needs to be confirmed on each PA authorization
![image](https://user-images.githubusercontent.com/122046056/227037729-70ed3eb1-5eec-41fe-8ef5-55d01bc78499.png)
